Results 111 to 120 of about 39,201 (181)

The impact of remdesivir on SARS-CoV-2 evolution in vivo

JCI Insight
The impact of remdesivir on SARS-CoV-2 diversity and evolution in vivo has remained unclear. In this single-center, retrospective cohort study, we assessed SARS-CoV-2 diversification and diversity over time in a cohort of hospitalized patients who did or
Ted Ling-Hu, Lacy M. Simons, Estefany Rios-Guzman, Alexandre Machado Carvalho, Maria Francesca R. Agnes, Arghavan Alisoltanidehkordi, Egon A. Ozer, Ramon Lorenzo-Redondo, Judd F. Hultquist   +8 more
doaj   +1 more source

Incidence of COVID-19 Symptom Rebound After Treatment with Remdesivir

Background/Objectives: Recent in vitro data suggest that remdesivir might be less likely than nirmatrelvir–ritonavir to be associated with COVID-19 rebound.
Rebecca Madjarov, Judith Strymish, William J. O’Brien, Anna Chen, Michael E. Charness, Kalpana Gupta, Katherine Linsenmeyer   +6 more
core   +1 more source

Severe myocardium suppression in two congenital heart disease patients after remdesivir use – a case report

BMC Pediatrics
Background Remdesivir, the first FDA-approved antiviral for SARS-CoV-2, has shown clinical benefits in early COVID-19 but is associated with cardiac adverse events.
Yi-Fan Lin, Shih-Yu Fang, Shu-Chien Huang, En-Ting Wu   +3 more
doaj   +1 more source

Remdesivir and the Liver: A Concise Narrative Review of Remdesivir-Associated Hepatotoxicity in Patients Hospitalized Due to COVID-19

Severe acute respiratory syndrome coronavirus 2 has infected millions of people, but about 20% of infected individuals do not develop symptoms. COVID-19 is an inflammatory disease that affects a portion of individuals infected with the virus and it is ...
Alireza FakhriRavari, Mazyar Malakouti
core   +1 more source

Remdesivir nephrotoxicity in tubular epithelial cells. [PDF]

Front Pharmacol
Miño-Izquierdo L, Guerrero-Mauvecin J, Villar-Gómez N, Hernández M, Carrasco S, Castro-Gonzalez R, Cannata P, Sanchez-Niño MD, Ortiz A, Sanz AB.   +9 more
europepmc   +1 more source

Correction: Remdesivir-bisPropionate, a better derivative of remdesivir against SARS-CoV-2: Comparison of in vitro and in vivo PK/PD Study as well as its therapeutic potential. [PDF]

PLoS One
Chakraborty A, Diwan A, Chiniga V, Arora V, Thakur Y, Tatake J, Pandey R, Holkar P, Holkar N.   +8 more
europepmc   +1 more source

First Report on Remdesivir Use for the Treatment of Respiratory Syncytial Virus in Five Allogeneic Hematopoietic Cell Transplant Recipients. [PDF]

J Infect Dis
McCulloch DJ, Khawaja F, Tverdek FP, Ford ES, Vora SB, Waghmare A, Vuong N, Chemaly RF, Hill JA.   +8 more
europepmc   +1 more source

Marburg virus disease outbreak and response in South Ethiopia Region. [PDF]

Int J Emerg Med
Wolie AA, Mengistie BT, Mengistie CT, Tadesse SZ, Teferi MG, Bifa GW, Bogale AA, Adnew AJ, Admassu NK, Bayu TG, Nigatu DG, Gemeda AS, Teko EB, Roffe E, Hassen GW.   +14 more
europepmc   +1 more source

Virologic insights from the phase 3 REDPINE trial: remdesivir in renally impaired and immunocompromised patients with COVID-19. [PDF]

Antimicrob Agents Chemother
Rodriguez L, Andreatta K, Chen S, Hu Y, Li J, Martin R, Han D, Moshiri J, Perry JK, Sise ME, Santos JR, Plate M, McPhail MJ, Koullias Y, Hyland RH, Hedskog C.   +15 more
europepmc   +1 more source

Effect of Remdesivir on Mortality in Mechanically Ventilated COVID-19 Patients: A Target Trial Emulation Using Inverse Probability of Treatment Weighting. [PDF]

Infect Drug Resist
Wang YR, Jhou HJ, Chen PH, Lin TY.
europepmc   +1 more source